SGLT-2 Therapy Center

SGLT-2 inhibitors are a class of drugs that are used to treat type 2 diabetes. They work by blocking the reabsorption of glucose in the kidneys, allowing glucose to be excreted in the urine. As a result, they can help to reduce blood glucose levels and improve glycemic control. In …

Patients with cardiac implantable electronic devices (CIEDs) who received an SGLT2i had a significantly lower incidence of atrial arrhythmia (AA) compared to placebo. 

DAPA-CKD trial results indicate a significant benefit for SGLT2 inhibitor dapagliflozin in reducing chronic kidney disease progression and mortality caused by kidney failure and cardiovascular disease, regardless of diabetes status. 

Dapagliflozin (Farxiga®) has been granted U.S. Food and Drug Administration (FDA)  Breakthrough Therapy Designation (BTD) for patients with chronic kidney disease (CKD), whether or not they have type 2 diabetes. 

In addition to clinical trials, does data from a meta-analysis of retrospective cohort studies support the benefits of SGLT-2 inhibitors?

Black patients may have lower odds of achieving target HbA1C levels on metformin and SGLT2 alone. 

Sodium-glucose cotransporter 2 (SGLT2) inhibitors were created to treat diabetes, but noted to ameliorate cardiovascular events. 

The case for why an SGLT2 inhibitor or GLP-1 receptor agonist should be initiated early in diabetes treatment, regardless of whether the patient is on insulin therapy.

The interaction between systolic blood pressure (SBP) and the effects of empagliflozin in patients with heart failure with reduced ejection fraction (HFrEF).

Dapagliflozin is well studied in type 2 diabetes mellitus and HF and CKD patients with positive results and a good safety profile.